Abstract
BackgroundJanus activated kinase (Jak) inhibition has shown clinical benefits in treatment of rheumatoid arthritis (RA). However, targeting all isoforms of Jak (Jak1, Jak2, Jak3, and Tyk2) may be associated with...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have